Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)

Group 1 - A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. for misleading investors regarding its lead cell therapy candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [1] - The lawsuit alleges that Capricor concealed adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial, while falsely suggesting they could obtain first approval for DMD cardiomyopathy [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied Capricor's Biologics License Application, the stock price fell from $11.40 to $7.64 per share [3] Group 2 - Investors who acquired shares of Capricor are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on September 15, 2025 [4]